The Associated Press reports this morning that Fred Baron received Biogen’s drug Tysabri to use as an experimental treatment for multiple myeloma “after a ‘legal basis’ for its use was found.”
We’re not quite sure what the legal obstacle might have been, but we wish both Baron and Biogen the best.